Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06755801 | NOT YET RECRUITING | ANOCA - Angina With Non-obstructive Coronary Arteries

Nebivolol ANOCA Treatment Randomized Trial
Sponsor:

Spanish Society of Cardiology

Information provided by (Responsible Party):

Fernando Alfonso

Brief Summary:

To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.

Condition or disease

ANOCA - Angina With Non-obstructive Coronary Arteries

Coronary Microvascular Dysfunction (CMD)

Intervention/treatment

Nevibolol

Placebo

Phase

PHASE3

Detailed Description:

Objective To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction. Hypothesis Treatment with titrated nebivolol will result superior to placebo in symptoms control in patients presenting with coronary microvascular disease (CMD). Study design Prospective, multicenter, controlled, double-blinded, randomized clinical trial. Inclusion criteria • Patients over 18 years old with symptoms or evidence of myocardial ischemia and coronary arteries without lesions or with epicardial lesions (\<50% by visual estimation or FFR \>0.80 / RFR \>0.90), and • CFR ≤ 2.0 and/or IMR≥25 Exclusion criteria Life expectancy \<1 year, inability to provide informed consent, severe valve disease, left ventricular ejection fraction \<30%, clinical contraindication for betablockers treatment. Treatment arms Randomization will be performed after invasive diagnostic of CMD: Study group: Nebivolol • Patients will start with a dose of 5 mg every 24 hours. Biweekly dose adjustments will be performed during the first two months, increasing the dose (if tolerated with respect to heart rate, blood pressure, and symptoms) up to a maximum of 20 mg/24 hours. Control group: Placebo • Patients will be treated with one tablet every 24 hours. Primary endpoint: The effectiveness of nebivolol treatment in improving angina symptoms was measured using the SAQ questionnaire after 6 months of treatment. Secondary endpoints • Quality of life at 6 months. * Functional capacity at 6 months. * Major cardiac events at 1 year.

Study Type : INTERVENTIONAL
Estimated Enrollment : 150 participants
Masking : QUADRUPLE
Primary Purpose : TREATMENT
Official Title : Microvascular Obstruction Treatment and Outcomes Randomized Study.
Actual Study Start Date : 2025-04-01
Estimated Primary Completion Date : 2026-03-30
Estimated Study Completion Date : 2026-09-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Age 18 years or older.
  • * Presence of stable angina symptoms, defined as compatible symptoms occurring at least once weekly in the last three months.
  • * Absence of functionally significant epicardial coronary artery disease (FFR \> 0.80).
  • * Microvascular functional study showing CFR\< 2,0 and/or IMR ≥ 25.
Exclusion Criteria
  • * Allergy or contraindication to the use of beta-blockers.
  • * Indication for beta-blocker treatment due to another pathology.
  • * Ventricular dysfunction (LVEF \< 45%).
  • * Percutaneous coronary revascularization in the last 6 months.
  • * History of surgical revascularization.
  • * First-degree atrioventricular block or bifascicular block.
  • * Presence of hemodynamically significant valvulopathy.
  • * Presence of cardiomyopathy or congenital cardiac anomaly.
  • * Severe renal insufficiency (eGFR \< 30 ml/min).
  • * Liver failure (history of cirrhosis or transaminase elevation \> 3 times the upper limit of normal).
  • * Pregnant or lactating women.
Nebivolol ANOCA Treatment Randomized Trial

Location Details

NCT06755801

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found